RegulatoryOfficial
European Commission authorises Sanofi's rabies vaccine VaxRabeo through the centralised procedure
🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026
Commission Decision (2026) 8231 of 12 November 2026 grants Sanofi Winthrop Industrie an EU-wide marketing authorisation for the inactivated human rabies vaccine.
The European Commission has granted a new centralised marketing authorisation for VaxRabeo, an inactivated rabies vaccine for human use. The authorisation was issued by Commission Decision (2026) 8231 on 12 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026